No Cover Image

Journal article 489 views 68 downloads

Response to insulin glargine 100 U/mL treatment in newly-defined subgroups of type 2 diabetes: Post hoc pooled analysis of insulin-naïve participants from nine randomised clinical trials

Wolfgang Landgraf Orcid Logo, Gregory Bigot, Brian M. Frier, Geremia B. Bolli, David Owens Orcid Logo

Primary Care Diabetes, Volume: 17, Issue: 4, Pages: 379 - 385

Swansea University Author: David Owens Orcid Logo

  • 63334.VOR.pdf

    PDF | Version of Record

    Crown Copyright © 2023 Published by Elsevier Ltd on behalf of Primary Care Diabetes Europe. Distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).

    Download (2.37MB)

Check full text

DOI (Published version): 10.1016/j.pcd.2023.04.010

Abstract

Aims: To assess insulin glargine 100 U/mL (IGlar-100) treatment outcomes according to newly-defined subgroups of type 2 diabetes mellitus (T2DM). Methods: Insulin-naïve T2DM participants (n = 2684) from nine randomised clinical trials initiating IGlar-100 were pooled and assigned to subgroups “Mild...

Full description

Published in: Primary Care Diabetes
ISSN: 1751-9918
Published: Elsevier BV 2023
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa63334
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract: Aims: To assess insulin glargine 100 U/mL (IGlar-100) treatment outcomes according to newly-defined subgroups of type 2 diabetes mellitus (T2DM). Methods: Insulin-naïve T2DM participants (n = 2684) from nine randomised clinical trials initiating IGlar-100 were pooled and assigned to subgroups “Mild Age-Related Diabetes (MARD)”, “Mild Obesity Diabetes (MOD)”, “Severe Insulin Resistant Diabetes (SIRD)”, and “Severe Insulin Deficient Diabetes (SIDD)”, according to age at onset of diabetes, baseline HbA1c, BMI, and fasting C-peptide using sex-specific nearest centroid approach. HbA1c, FPG, hypoglycemia, insulin dose, and body weight were analysed at baseline and 24 weeks. Results: Subgroup distribution was MARD 15.3 % (n = 411), MOD 39.8 % (n = 1067), SIRD 10.5 % (n = 283), SIDD 34.4 % (n = 923). From baseline HbA1c 8.0–9.6% adjusted least square mean reductions after 24 weeks were similar between subgroups (1.4–1.5 %). SIDD was less likely to achieve HbA1c < 7.0 % (OR: 0.40 [0.29, 0.55]) than MARD. While the final IGlar-100 dose (0.36 U/kg) in MARD was lower than in other subgroups (0.46–0.50 U/kg), it had the highest hypoglycemia risk. SIRD had lowest hypoglycemia risk and SIDD exhibited greatest body weight gain. Conclusions: IGlar-100 lowered hyperglycemia similarly in all T2DM subgroups, but level of glycemic control, insulin dose, and hypoglycemia risk differed between subgroups.
Keywords: Clustering, C-peptide, Type 2 diabetes, Randomised clinical trial, Insulin glargine
College: Faculty of Medicine, Health and Life Sciences
Issue: 4
Start Page: 379
End Page: 385

Similar Items